Excelsior Biopharma Inc.
Research Excelsior Biopharma Inc. (6496.TWO) on Bullrun: market cap TWD 1.11B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6496.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyTWD
- Market capTWD 1.11B
- Financial periodQ2 2026
- RevenueTWD 232.49M
- Net income-TWD 57.46M
- Free cash flow-TWD 23.74M
- Gross margin37.8%
Valuation Snapshot
latest market cap is TWD 1.11B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 1.11B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About Excelsior Biopharma Inc.
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specialty medicine and public health products.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Excelsior Biopharma Inc.'s market cap?
Excelsior Biopharma Inc.'s market capitalization is TWD 1.11B.
What does Excelsior Biopharma Inc. do?
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specialty medicine and public health products.